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Introduction
Gliomas are the commonest central nervous system 
(CNS) neoplasms worldwide including Asia and Africa 
(Ahmad et al., 2010; Trabelsi et al., 2014; Zahir et al., 
2014). Central Neurocytoma is a rare tumor with a 
favorable prognosis and is composed of uniform, small 
round cells with neuronal differentiation. It is typically 
located in the lateral ventricles of the brain especially 
near the foramen of Monro but can also be located in the 
third and even fourth ventricles, occurs mostly in young 
adults and histologically corresponds to WHO Grade 
II (Dodero et al., 2000; Figarella-Branger et al., 2007). 
Extraventricular tumors with a similar histology and 
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Abstract
 Background: Central neurocytomas are rare neuronal neoplasms with a favorable prognosis. They are 
typically located in the lateral ventricles of the brain and mostly histologically correspond to WHO grade II 
with a Mib 1 labelling index of <2%. Similar tumors located in the cerebral hemispheres and spinal cord, for 
example, are called “extraventricular neurocytomas”. A few tumors histologically show atypia, mitoses, vascular 
proliferation and/or necrosis and a Mib 1 index >2 % and are designated as “atypical neurocytomas. Aim: The 
aim of our study was to describe the common as well as unusual morphologic features and the role of various 
immunohistochemical stains in the diagnosis of these rare tumors. Materials and Methods: We retrieved and 
reviewed 35 cases diagnosed between 2001 and 2015. Results: Sixty percent of patients were males, and the mean 
age was 26 years. 31 cases (88.6%) were intraventricular and 4(11.4%) were extraventricular. Histologically, 
6 cases (17.1%) were compatible with “atypical neurocytomas”. All cases showed the classic morphology 
comprising nests and sheets of uniform, round cells with uniform round to oval nuclei with finely speckled 
chromatin and perinuclear cytoplasmic clearing (halos). All cases also showed delicate, fibrillary, neuropil-like 
matrices. Other common histologic features included capillary-sized blood vessels in a branching pattern in 
57.1%, foci of calcification in 34.3% and perivascular pseudorosettes in 20%. Rare findings included Homer-
Wright or true rosettes in 8.6% and ganglioid cells in 2.9%. Synaptophysin was the most consistent and valuable 
marker, being positive in almost all cases. GFAP positivity in tumor cells was seen in 25.7% of cases. Follow up 
was available in 13 patients. Of these 9 had histologically typical and 4 had atypical tumors. Only 1 (with an 
atypical neurocytoma) died, probably due to complications of surgery within one month, while 12 (including 
3 with atypical neurocytomas) remained alive. Recurrence developed in 1 of these 12 patients (histologically 
consistent with typical morphology) almost 9 years after surgery. Only 4 patients, including 2 with atypical 
tumors, received postoperative radiotherapy, all with surgery in 2010 or later. Overall, prognosis was excellent 
with prolonged, recurrence free survival and most patients, even without receiving radiation therapy, were alive 
and well for many years, even a decade or more after surgery, without developing any recurrence, indicating 
the benign nature of these neoplasms. 
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located in the cerebral hemispheres or spinal cord are 
called “extraventricular neurocytomas” or EVNs (Figarella 
et al., 2007; Brat, 2010). EVNs need to be distinguished 
from the usual more common oligodendrogliomas 
which have a relatively worse prognosis (Atalay et 
al., 2015). The tumor cells are mature neurons which 
resemble neurocytes similar to those normally found in 
the dentate fascia of hippocampus and in the cerebellum 
and were first described as ‘ neuronal’ by Hassoun et al 
in (Hassoun et al., 1993). In the past, the intraventricular 
central neurocytomas were often confused with other 
intraventricular tumors especially ependymomas, 
oligodendrogliomas, subependymomal astrocytomas etc. 
However, immunohistochemistry has greatly improved 
Zubair Ahmad et al
Asian Pacific Journal of Cancer Prevention, Vol 17, 20161566
the diagnostic accuracy (Conrad et al., 2000). The tumor 
cell nuclei have finely speckled chromatin and cytoplasm 
is clear. Thus these tumors need to be distinguished from 
other clear cell tumors (Bonney et al., 2015). Central 
neurocytomas usually have Mib 1 (ki 67) labeling index 
of less than 2%. Some central neurocytomas have an 
index higher than 2%, histologically show mitoses, 
vascular proliferation and/or necrosis, and demonstrate 
a significantly shorter recurrence free interval. Such 
tumors are called “atypical central neurocytomas” 
(Soylemezoglu et al., 1997; Chou et al., 1999; Mackenzie, 
1999). However, so far, such atypical lesions have not 
been assigned a higher WHO grade. The same histologic 
criteria and Mib 1 labeling index threshold can also be 
used to designate extraventricular lesions-atypical EVNs 
(Brat, 2010). Most cases reported in literature including 
extraventricular and atypical neurocytomas are single 
case reports or case series involving two or more cases. 
The aim of this study is to present the cases of Central 
(and extraventricular) Neurocytomas diagnosed in our 
department, the largest center for histopathology in 
Pakistan, over a period of almost 15 years. Our department 
is a major referral center for challenging and difficult 
cases covering all subspecialties including brain tumors, 
from all over Pakistan. We hope that this series of cases 
will be an important addition to the available literature 
on these rare tumors.
Materials and Methods
Slides of all cases reported as Neurocytomas 
between Jan 1, 2001 and June 30, 2015 in the Section of 
Histopathology, Department of Pathology and Laboratory 
Medicine, Aga Khan University Hospital, Karachi were 
retrieved and reviewed by the two principal authors 
(ZA and NU). All cases were fixed in 10% buffered 
formalin and embedded in paraffin wax. Sections were 
cut at thickness of 5 microns and were routinely stained 
with Hematoxylin and Eosin (H&E). Five microns thick 
unstained sections were also cut from paraffin blocks 
for performing Immnunohistochemistery (IHC). These 
unstained sections were deparaffinized in xylene, hydrated 
in decreasing concentrations of alcohol solution and 
then washed in Tris Buffer. IHC staining was performed 
using avidin-biotin-peroxidase method (Sigma, St Louis, 
MO). IHC antibodies used included Glial Fibrillary 
Acidic Protein (GFAP) polyclonal, ready to use -Dako 
Corporation, (Carpenteria, California; Synaptophysin- 
monoclonal, Ready to use, Dako Cytomation, Denmark; 
Mib 1 (Ki 67)- monoclonal, ready to use, Dako cytomation, 
Denmark, in most cases. In selected cases, Chromogranin 
A, monoclonal, ready to use, Dako cytomation, Denmark; 
and Cytokeratin AE1/AE3 (Monoclonal, ready to use, 
Dako cytomation), Denmark were also used. All data 
was analyzed using SPSS 19.0 version software package.
Results 
A total of 35 cases of Central Neurocytoma were 
reported during the study period (2001-2015). Out of 
35, 21 patients (60%) were males while 14(40%) were 
females. Male to fem ale ratio was 1:5:1. Age range 
was 9 to 51 years. Mean and median age was 26 and 
27 years respectively. Out of 35 cases, 31 (88.6%) were 
intraventricular, while 4 (11.4%) were extraventricular. Of 
the 31 intraventricular tumors, 29 (93.5%) were located 
in the lateral ventricles and 2 (6.5%) were located in the 
third ventricle. The 4 extraventricular tumors were located 
in the corpus callosum, thalamus, left temporoparietal 
hemisphere and the suprasellar region respectively. 
Histologically, 6 out of 35 (17.1%) were compatible with 
“atypical central neurocytoma.” Of these, 5 cases were 
intraventricular in location while 1 case was located in 
the corpus callosum. The other 29 tumors (82.9%) were 
all histologically compatible with the usual grade II 
central neurocytomas. Histologically, all cases showed 
nests and/or sheets of uniform round cells with uniform 
round to oval nuclei having finely speckled chromatin, 
Table 1. Atypical Neurocytomas in Our Study (n=6)
Serial 
Number Location
Year of 
surgery Mitoses/10HPFs Mib 1(Ki 67) Follow up
1 Intraventricular 2007 3 2-5% Not available
2 Extraventricular (suprasellar) 2010 >3 >5% Died within a month after surgery
3 Intraventricular* 2010 3 >5% Not available
4 Intraventricular 2012 3 2-5% Alive and well. No recurrence
5 Intraventricular** 2015 >3 >5% Alive and well. No recurrence
6 Intraventricular* 2015 >3 >5% Alive and well. No recurrence
*Showed vascular proliferation on histological examination; ** Showed necrosis on histological examination
Figure 1. A) Typical Central neurocytoma exhibiting 
uniform small cells with intervening chicken wire 
vessels (H&E, 400x magnification) and B) perinuclear 
halos (H&E, 400x magnification). C) Foci of nuclear 
free zones (H&E, 200x magnification). The Ki 67 index 
is less than 2% (D)
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inconspicuous nucleoli, and perinuclear cytoplasmic 
clearing (perinuclear halos). All cases showed delicate, 
fibrillary neuropil like matrix (Figure 1A-D). Among other 
histological features, the 6 “atypical” cases demonstrated 
cellular atypia, increased mitotic activity and Mib 1 (Ki 
67) labeling indices above 2% (Figure 2A-D). However, 3 
of the 6 showed >3 mitoses/10HPF while 4 of the 6 showed 
Mib 1 labeling indices >5% (Table 1).Of these 6 atypical 
neurocytomas, 3 showed microvascular proliferation and 
1 case also showed necrosis (Figure 2C). These were the 
only cases in the entire series which showed microvascular 
proliferation and/or necrosis. Scattered mitotic activity 
Table 2. Immunohistochemical Staining in Our Cases (n=35)
Serial number Immunohistochemical stain Positive Negative Not performed
1 Synaptophysin 31 (86.6%) 1 (2.9%) 3 (8.6%)
2 GFAP 9 (25.7%) 21 (60%) 5 (14.3%)
3 S 100 protein 6 (17.1%) 1 (2.9%) 28 (80%)
4 Chromogranin A 8 (22.8%) 8 (22.8%) 19 (54.3%)
5 Neuron specific enolase (NSE) 8 (22.8%) 2 (5.8%) 25 (71.4%)
6 CD 56 3 (8.6%) 1 (2.9%) 31 (88.6%)
7 Neurofilament (NF) - 3 (8.6%) 32 (91.4%)
8 CD 99 (Mic 2) - 8 (22.8%) 27 (77.2%)
9 Epithelial membrane antigen (EMA) 3 (8.6%) 9 (25.7%) 23 (65.7%)
10 Cytokeratin AE1/AE3 - 9 (25.7%) 26 (74.3%)
Table 3. Follow Up of Patients in Our Series (n=13)
Serial Number Year of surgery Histology Location Radiation treatment Recurrence Follow up
1 2002 Typical Ventricular No No Alive
2 2003 Typical Ventricular No No Alive
3 2004 Typical Ventricular No No Alive
4 2006 Typical Ventricular No Yes, in 2015 Alive
5 2009 Typical Ventricular No No Alive
6 2010 Atypical Extraventricular No No Died within a month of surgery
7 2010 Typical Extraventricular Yes No Alive
8 2010 Atypical Ventricular No No Alive
9 2012 Atypical Ventricular Yes No Alive
10 2012 Typical Ventricular Yes No Alive
11 2012 Typical Extraventricular No No Alive
12 2015 Typical Ventricular No No Alive
13 2015 Atypical Ventricular Yes No Alive
Figure 2. A) An atypical central neurocytoma exhibiting 
increased cellularity (H&E, 200x magnification). B) 
Foci showing cytologic atypia and C) a single focus 
of vascular proliferation is seen in small arrow(H&E, 
400x magnification). Increased Ki 67 index (>10%) 
is seen (D)
Figure 3. A) Foci of coarse calcification in central 
neurocytoma (H&E, 200x magnification). B) Focus 
of perivascular  and C) Homer Wright rosettes 
. D) Scattered ganglioid cells (large arrow) and 
multinucleated giant cells (small arrow) [H&E, 400x 
magnification]
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and mild or focal atypia were seen in another 8 cases. 
Hence, a total of 14 out of 35 cases (42.9%) showed at 
least focal atypia and scattered mitotic activity. Capillary 
sized vessels, arranged in many cases in a branching or 
arborizing pattern were seen in 20 cases (57.1%). Foci 
of calcification (Figure 3A) were seen in 12 out of 35 
cases (34.3%). Less frequent histologic findings included 
perivascular pseudorosettes (Figure 3B) seen in 7 cases 
(20%), Homer Wright (Figure 3C) or true rosettes seen 
in 3 cases (8.6%), and ganglioid cells (Figure 3D) seen 
in only 1 out of the total 35 cases (2.9%). 
In 19 (54.3%) out of 35 cases, the only clinical details 
provided were those of an intraventricular tumor/mass. In 
the remaining 16 cases, the clinical signs and symptoms 
included headache (in 12(34.3%) cases), vomiting (in 
3 cases), seizures (in 2 cases), urinary and/or fecal 
incontinence (in 2 cases), difficulty in walking (in 2 cases) 
and personality changes (in 2 cases). The following signs 
and symptoms were seen in 1 case each: decrease in vision, 
diplopia, papilledema, vertigo and pain in lower limb.
On immunohistochemistry, synaptophysin was the 
most consistent and reliable marker being positive in 
almost all cases in which it was performed. GFAP was 
mostly negative but showed focal positivity in tumor cells 
in some cases. The details of immunohistochemical stains 
analyzed in our cases are shown in Table 2.
Follow up was unfortunately available in only 13 out 
of 35 cases (37.1%). The details are shown in Table 3.
Discussion
The incidence rate of Central Nervous System (CNS) 
neoplasms has risen more than 40% in the last two decades 
(Zahir et al., 2014). Central neurocytomas are rare in our 
practice and composed about 0.7% of all CNS neoplasms 
in a study carried in our department (Ahmad et al., 2010). 
In our series of 35 patients, 60% were males, mean age 
was 26 years, 88.6% tumors were intraventricular, and 
93.5% of intraventricular tumors were located in the 
lateral ventricles. There were 4 extraventricular tumors 
comprising 11.4% of the total while 6 (17.1%) were 
histologically compatible with atypical neurocytomas 
with Mib 1 (ki 67) levels greater than 2%. Only 1 of the 6 
atypical neurocytomas was extraventricular. Studies have 
shown that this tumor affects males and females almost 
equally, and mainly affects young adults. Mean age was 
29 years in one study (Tacconi et al., 1997; Conrad et 
al., 2000; Figarella-Branger et al., 2007). Tacconi et al 
published a series of 5 cases in 1997 and stressed the 
importance of diagnostic suspicion, total surgical excision 
and radiotherapy in the prognosis of this tumor (Tacconi 
et al., 1997). In the year 2000, a number of studies were 
published on central neurocytomas. Conrad et al published 
a clinicopathological analysis of 3 cases in which they 
discussed the clinical and radiological features, surgical 
findings and pathological appearance of this tumor (Conrad 
et al., 2000). The same year Dodero et al reported 2 cases 
of ‘giant’ central neurocytomas in two young women with 
both cases showing triventricular extension (Dodero et 
al., 2000). In a series of 10 cases, Favereaux et al, also in 
2000, discussed the histopathological variants of central 
neurocytoma. In their series, 2 out of 10 cases fulfilled 
the histological criteria for atypical neurocytomas. These 
2 cases showed less marked reactivity for the neuronal 
marker Synaptophysin compared to the 8 “classical” cases. 
Their 2 atypical cases were cellular with increased mitotic 
activity. One case also showed tumor necrosis. Both their 
atypical cases had Mib 1 labeling index >5.2% and both 
tumors recurred. Based on this, they concluded that high 
mitotic activity, necrosis, loss of neuronal differentiation 
on immunohistochemistry and high Mib 1 labeling 
index were the histological and immunohistochemical 
criteria for aggressive behavior (Favereaux et al., 2000). 
Chou et al reported a case of atypical neurocytoma. The 
histology in their case showed up to 3 mitoses/10HPF 
and Mib 1 labeling index was 5%. Their patient died 
of hydrocephalus and brain edema the day after he 
underwent partial resection. They noted that atypical 
neurocytomas require postoperative radiotherapy (Chou et 
al., 1999). In a comprehensive review published in 2006, 
Sharma et al discussed the epidemiology, histogenesis, 
clinical presentation, the characteristic neuroimaging 
and histopathologic findings and the therapeutic options. 
They concluded that safe maximal resection is the best 
therapeutic option and shows the best long term results 
when taking into account the local control of the tumor 
and long term survival of the patient. They emphasized 
the beneficial effect of adjuvant radiotherapy in atypical 
neurocytomas and when the tumor is incompletely resected 
(Sharma et al., 2006). Ulivieri and Oliveri described a 
single case in a 25 year old male in 2007 (Ulivieri and 
Oliveri, 2007). However, two relatively large series (of 
9 cases each) were published in 2008. The first of these 
published by Chen et al demonstrated high proliferative 
index (Mib 1 labeling index upto 6.8%) in two patients in 
whom the disease recurred. They also showed that apart 
from high proliferation index, vascular proliferation and 
synaptophysin expression were more prominent in the 
recurrent tumors compared to the primary. However, 
they concluded that recurrent tumors are usually local 
and patients undergo full recovery following a second 
surgical resection and radiotherapy (Chen et al., 2008). 
This indicates that Mib 1 (Ki 67) labeling index is a 
valuable prognostic factor in Neurocytomas, and not just 
in gliomas, where its role as a prognostic factor is well 
established (Chen W-T et al., 2015). The other study by 
Chen et al, which also looked at nine cases, followed 
the patients for 8 to 33 months after surgery and used 
various methods to assess the functional outcomes of 
central neurocytomas. They found that most of the patients 
achieved good functional outcomes and showed good 
ability to perform their daily activities independently. 
They recommended that although these tumors are mostly 
benign, patients should be regularly followed up in order 
to detect any recurrence of the tumor (Chen et al., 2008).
A multidisciplinary review by Chodhari et al published 
in 2009 concluded that recurrence rate for central 
neurocytomas after surgery was more common than 
previously thought. The authors therefore recommended 
a multi-modality team involvement for optimum 
management of these tumors (Chodhari et al., 2009). 
Chen et al published a series of ten cases in 2012, nine 
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of which were located in the lateral ventricles while one 
case was extraventricular (in the sellar region). Following 
surgical resection, six patients (four with subtotal and 
two with total resection) received radiotherapy. None of 
the tumors in their series recurred (Chen et al., 2012). 
Kane et al published a remarkably large series in 2012 
solely on intracranial extraventricular neurocytomas 
(EVNs). This series comprised 85 patients of whom 
27% had atypical EVNs on histologic examination. The 
authors demonstrated the better prognosis of typical 
EVNs compared to atypical EVNs following surgical 
resection. According to their findings typical EVNs had 
a 5-year recurrence rate of 36% and a 5 year mortality 
rate of 4% compared to 5 year recurrence rate of 68% 
and 5 year mortality rate of 44% for atypical EVNs. The 
difference was statistically significant (p <0.001). They 
also found that for both typical and atypical EVNs, gross 
total resection was more beneficial compared to subtotal 
resection and that radiotherapy (in both typical and 
atypical EVNs) benefited patients with subtotal resection 
of the primary tumor (Kane et al., 2012). Canova at al 
noted that the main treatment of central neurocytomas 
which is total resection is achieved in only half the cases. 
They argue that external beam radiotherapy was beneficial 
in patients with subtotal resection as well as in those 
with atypical central neurocytomas. They also discussed 
the role of chemotherapy in patients with extracranial 
and/or neuromeningeal spread of the tumor, and in 
tumors which recurred after surgery and/or radiotherapy 
(Canova at al., 2014). In a recent study published in 2015, 
Bonney et al looked at the molecular biology of central 
neurocytomas and acknowledged that although progress 
on this front was being made, this had not yet translated 
into the development of targeted therapies for these tumors 
(Bonney et al., 2015). A recent 2015 article by Yang et 
al focused on the clinical manifestations of these tumors 
and concluded that although no clinical feature was 
pathognomonic, patients typically presented with signs 
and symptoms of increased intracranial pressure (Yang 
et al., 2015). Other authors also agree that manifestations 
of increased intracranial pressure usually brought these 
tumors to clinical attention (Chen et al., 2008; Chen et al., 
2012; Canova et al., 2014). Kawano et al recently reported 
a case of atypical EVN in a 3 year old girl. Atypical EVN 
in children are extremely rare. However, the authors argue 
that atypical EVN should be considered in the differential 
diagnosis of an intracranial but extraventricular cystic 
tumor in children (Kawano et al., 2015).
In a comprehensive review on extraventricular 
neurocytomas, published in 2014, Patil et al discussed 
the clinical and pathologic features of these tumors, the 
effectiveness of surgical resection and progression free 
survival. Of their seven cases, ages 7 to 65 years, four 
were located in the cerebral hemispheres, and 1 each in 
the cerebellum, pineal gland and spinal cord. They found 
that gross total resection and subtotal resection plus 
radiotherapy had similar outcomes, while extremes of age 
and atypical histology adversely affected the prognosis 
(Patil et al., 2014). A recent article by Sweiss et al also 
reviewed EVNs including their epidemiology, clinical and 
radiological findings, locations, treatment and prognosis 
and concluded that being quite rare, the epidemiology of 
EVNs was not definitely known and they were associated 
with a poor prognosis compared to central neurocytomas. 
They argued that effective treatment strategies for these 
rare tumors were still lacking (Sweiss et al., 2015).
The detailed discussion above clearly highlights the 
importance of adjuvant radiotherapy in the treatment of 
both central and extraventricular neurocytomas especially 
in the presence of subtotal resection. Various studies 
discussed above clearly demonstrate that radiotherapy 
increases local control of the tumor. However, a study by 
Vrana et al in 2013, while acknowledging the usefulness 
and importance of adjuvant radiotherapy in neurocytomas 
cautioned that the timing of radiotherapy in these patients 
needed to be considered carefully to protect these patients 
from possible late side effects of radiotherapy since most 
patients with neurocytomas have long time survival 
following treatment (Vrana et al., 2013).
In addition to the usual microscopic findings, rare 
features such as Homer Wright and true rosettes and 
ganglioid cells were seen in 3 and 1 of our 35 cases 
respectively. These rare features have been described in 
these tumors (Robbins et al., 1995).
Synaptophysin is the most reliable immunohistochemical 
marker in these tumors and diffuse positivity is seen in the 
neuropil, the fibrillary zones and perivascular nuclear-free 
zones (Figarella-Branger et al., 1992). Synaptophysin 
was also the best marker in our series being positive in 
almost all cases in which it was performed. Neu N and 
anti-HU antibodies are also considered to be very useful 
and demonstrate nuclear staining in most cases (Gultekin 
et al., 1998; Soylemezoglu et al., 2003). Unfortunately, 
we do not have Neu N and anti-HU antibodies in our 
immunohistochemistry panel as there are issues of 
financial feasibility. GFAP staining has been mostly 
reported in trapped reactive astrocytes, however some 
authors have reported GFAP positivity in tumor cells 
(von Deimling et al., 1990). As shown in the results, 
GFAP positivity was seen in focal cells in over 25% of 
our cases. Chromogranin A and Neurofilament are usually 
negative in central neurocytomas (Hassoun et al., 1993). 
Neurofilament was performed in only 3 of our cases and 
was negative in all 3. However, chromogranin A which 
was performed in almost 45% of our cases was positive 
in half of these. It also needs to be noted that diffuse, 
widespread expression of the immunohistochemical stain 
OLIG 2 helps in differentiating central neurocytomas 
(usually negative or focally positive in a minority of cases) 
and clear cell ependymomas from oligodendrogliomas 
(widespread OLIG 2 expression in almost all cases 
(Preusser et al., 2007).
Follow up was available in only 13 out of 35 cases. 
This is unfortunate but perhaps inevitable considering 
that we receive cases from all over Pakistan, a country 
of 180 million people, and many cases come from far 
off and remote areas. A glance at Table 3 shows that 12 
out of 13 patients (in whom follow up was available) 
were alive at the time of follow up. Of the 4 patients 
with atypical neurocytomas (in whom follow up was 
available), 1 patient died within a month of surgery (in 
2010). This tumor was extraventricular and the patient 
Zubair Ahmad et al
Asian Pacific Journal of Cancer Prevention, Vol 17, 20161570
0
25.0
50.0
75.0
100.0
N
ew
ly
 d
ia
gn
os
ed
 w
ith
ou
t 
tr
ea
tm
en
t 
N
ew
ly
 d
ia
gn
os
ed
 w
ith
 t
re
at
m
en
t 
Pe
rs
is
te
nc
e 
or
 r
ec
ur
re
nc
e
Re
m
is
si
on
N
on
e
Ch
em
ot
he
ra
py
Ra
di
ot
he
ra
py
Co
nc
ur
re
nt
 c
he
m
or
ad
ia
tio
n
10.3
0
12.8
30.025.0
20.310.16.3
51.7
75.0
51.1
30.031.3
54.2
46.856.3
27.625.0
33.130.031.3
23.7
38.0
31.3
N
ew
ly
 d
ia
gn
os
ed
 w
ith
ou
t 
tr
ea
tm
en
t 
N
ew
ly
 d
ia
gn
os
ed
 w
ith
 t
re
at
m
en
t 
Pe
rs
is
te
nc
e 
or
 r
ec
ur
re
nc
e
Re
m
is
si
on
N
on
e
Ch
em
ot
he
ra
py
Ra
di
ot
he
ra
py
Co
nc
ur
re
nt
 c
he
m
or
ad
ia
tio
n
most likely died of complications arising after surgery. 
Of the other 3 patients (operated in 2010, 2012 and 
2015), 2 received postoperative radiation, all 3 were 
alive with no recurrence. Of all 13 patients, only 1 patient 
with an intraventricular typical central neurocytoma 
recently developed recurrence (in 2015), almost 9 years 
after surgery in 2006. This patient had not received any 
radiation treatment following initial surgery. Overall, out 
of 13, only 5 patients received radiation (all with surgery 
in 2010 or later). However, as shown in Table 2, patients 
with initial surgery as far back as 2002 and 2003, who 
did not receive any radiation treatment, are all alive and 
well at the time of recent follow up. The 3 patients with 
‘atypical’ neurocytomas also were alive and well at follow 
up. All had surgery witin the last three years (2 of them 
in 2015). They need to be followed for a longer time to 
determine their clinical behavior.
In conclusion, we present a series of 35 cases of 
neurocytoma including extraventicular and atypical 
neurocytomas that were diagnosed in our department 
over a period of almost 15 years. We hope that our series 
will be an important addition to the available literature 
on these rare tumors.
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